Pew Responds to White House's Drug Pricing Blueprint Information Request

Comments address administration’s questions on how federal, manufacturer programs affect spending

The Pew Charitable Trusts sent a letter July 16 to the U.S. Department of Health and Human Services, offering comments on the Trump administration’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Request for Information (RFI).

Pew’s response to the RFI addresses the following topics:

  • Federal program incentives.
  • Drug pricing structures and incentives.
  • Proposals to reform the Medicare Part B Competitive Acquisition Program.
  • Price reporting requirements and incentive structures.
  • Cost-shifting and cross-subsidization.
  • Generic drug pricing and development.
  • Pharmacy benefit managers and rebates.
  • 340B Drug Pricing Program.
  • Patient cost-sharing.